Skin Cancer section

Skin Cancer News & Features

Study Pools Data to Evaluate Melanoma Outcomes After Pembrolizumab

Among patients with advanced melanoma, the human PD-1-blocking antibody pembrolizumab was associated with an overall objective response rate of 33%, 12-month progression-free survival rate of 35%, and median overall survival of 23 months.

Melanoma Tumor Cells Respond Differently to Therapy in Elderly Patients Than in Younger Patients

Melanoma Tumor Cells Respond Differently to Therapy in Elderly Patients Than in Younger Patients

Therapy for the elderly with melanoma may be affected by findings that aged tumor cells in melanoma behave differently than younger tumor cells.

Sun Exposure Beneficial Despite the Risk of Melanoma

Sun Exposure Beneficial Despite the Risk of Melanoma

Though sunbathers are at an increased risk of developing skin cancer, women who sunbathe are likely to live longer than those who avoid the sun.

Microneedle Patch Delivers Localized Immunotherapy for Melanoma

Microneedles embedded in a patch deliver cancer immunotherapy treatment directly to the site of melanoma, according to preliminary findings in animal studies.

MC1R Variants May Increase Melanoma Risk, Even Without Sun Exposure

MC1R Variants May Increase Melanoma Risk, Even Without Sun Exposure

Variant of gene linked to skin pigmentation may be tied to higher melanoma risk.

Sign Up for Free e-newsletters

Regimen and Drug Listings

GET FULL LISTINGS OF TREATMENT Regimens and Drug INFORMATION

Bone Cancer Regimens Drugs
Brain Cancer Regimens Drugs
Breast Cancer Regimens Drugs
Endocrine Cancer Regimens Drugs
Gastrointestinal Cancer Regimens Drugs
Genitourinary Cancer Regimens Drugs
Gynecologic Cancer Regimens Drugs
Head and Neck Cancer Regimens Drugs
Hematologic Cancer Regimens Drugs
Lung Cancer Regimens Drugs
Other Cancers Regimens
Rare Cancers Regimens
Skin Cancer Regimens Drugs